2024/08/09
Shandong Xinbo helps Aafa Biology obtaining respiratory tract sympathetic virus MRNA vaccine clinical approval
On July 5, 2024, Hefei Afana Biotechnology Co., Ltd. independently developed a Class 1.2 biological product - respiratory syncytial virus mRNA vaccine (AFN0205), which was approved for clinical trials by the National Medical Products Administration (acceptance number: CXSL2400233)....